Glycopeptide Antibiotics Global Market Report 2024

The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be attributed to the escalating issue of antibiotic resistance, a rising incidence of infectious diseases, government initiatives, increased healthcare expenditure, and the globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to the emergence of infectious diseases, a growing geriatric population, persistent challenges related to antibiotic resistance, increased research and development investments and innovations, and the expansion of healthcare infrastructure. Major trends expected in the forecast period include the continued rise of antibiotic resistance, advancements in research and development, the impact of global health emergencies driving demand, collaborations for antibiotic stewardship, and market expansion in emerging economies.

The glycopeptide antibiotics market is anticipated to witness growth, driven by the increasing number of cancer and infectious disease cases. Cancer, characterized by uncontrolled cell multiplication and spread, and infectious diseases caused by various organisms such as bacteria, viruses, fungi, or parasites, are significant contributors to the demand for glycopeptide antibiotics. These antibiotics play a crucial role in treating infectious disorders caused by bacteria resistant to beta-lactams and other antibiotics. Additionally, in cancer patients, glycopeptide antibiotics enhance the antitumor effects of radiotherapy by targeting both the intended cancer cells and distant cancer cells elsewhere in the body. The American Cancer Society reported 1.9 million new cancer cases and 609,360 cancer deaths in the US in 2022. The rising prevalence of these conditions is expected to drive the growth of the glycopeptide antibiotics market.

The glycopeptide antibiotic market is also set to benefit from the increasing prevalence of gram-positive infections, caused by bacteria such as Staphylococcus aureus and Streptococcus pneumoniae. Glycopeptide antibiotics, with their unique mode of action targeting bacterial cell wall formation, are effective against many gram-positive bacteria. For example, according to the UK Health Security Agency's ESPAUR Report 2022-2023, Group A Streptococcus infections rose by 248% in 2022 compared to the previous year. This increase, even compared to pre-pandemic levels, emphasizes the growing prevalence of gram-positive infections and their role in propelling the glycopeptide antibiotic market.

A key trend in the glycopeptide antibiotics market is product innovation, with major companies focusing on developing innovative solutions. Leiden University, in October 2022, discovered new variants of the antibiotic vancomycin, which exhibited enhanced activity against gram-positive bacteria and lower nephrotoxicity compared to commercially used polymyxin antibiotics. This innovation aims to address the limitations of vancomycin, which is effective only against gram-positive strains.

Strategic partnerships are another notable trend in the glycopeptide antibiotics market, with major companies forming collaborations to bring revolutionary antibiotics to specific regions. In March 2022, Cumberland Pharmaceuticals Inc. announced a partnership with Tabuk Pharmaceutical Manufacturing Company to promote the Vibativ (telavancin) injection in the Middle East. Vibativ is crucial for patients with ventilator-associated pneumonia and hospital-acquired pneumonia caused by difficult-to-treat and multidrug-resistant Gram-positive bacterial infections.

In November 2021, ANI Pharmaceuticals Inc. acquired Novitium Pharma for $163.5 million, aiming to enhance its generics business and focus on specialized markets. Further, acquisitions are shaping the market dynamics, with companies seeking to strengthen their positions and expand their capabilities. Novitium Pharma, a new generic pharmaceutical corporation, contributes to ANI Pharmaceuticals Inc.'s growth and development in the pharmaceutical sector.

Major companies operating in the glycopeptide antibiotics market report are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Targanta Therapeutics, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

North America was the largest region in the glycopeptide antibiotics market in 2023. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary drugs within the glycopeptide antibiotics class include vancomycin, dalbavancin, oritavancin, and others. Vancomycin, for example, is a member of the glycopeptide antibiotics family, recognized for its ability to eliminate microorganisms in the intestines. It is used in the treatment of colitis, a condition that can develop after antibiotic therapy. These drugs are administered through oral, parenteral, and other routes for the treatment of various conditions such as skin and structure infections, meningitis, Clostridioides difficile infection, enterocolitis, and more. The end-users of these antibiotics include hospitals, specialty clinics, home care, and other healthcare providers.

The glycopeptide antibiotics market research report is one of a series of new reports that provides glycopeptide antibiotics market statistics, including glycopeptide antibiotics industry global market size, regional shares, competitors with a glycopeptide antibiotics market share, detailed glycopeptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the glycopeptide antibiotics industry. This glycopeptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.